ReviewStem cells (Dayton, Ohio)2019
Concise Review: Human Pluripotent Stem Cells for the Modeling of Pancreatic β-Cell Pathology.
Review in Stem cells (Dayton, Ohio), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 55 citations in OpenAlex.
- A dish-to-biobank framework links β-cell nutrient-stress programs to genetic and dietary risk for Type 2 Diabetes.bioRxiv : the preprint server for biology · 2026Article
- Review
- GRP94 is indispensable for definitive endoderm specification of human induced pluripotent stem cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Bcl-2 and Bcl-xL in Diabetes: Contributions to Endocrine Pancreas Viability and Function.Biomedicines · 2025Review
- Molecular profiling of NOD mouse islets reveals a novel regulator of insulitis onset.Scientific reports · 2024Article
- Heterozygous missense variant in GLI2 impairs human endocrine pancreas development.Nature communications · 2024Article
- Cell identity dynamics and insight into insulin secretagogues when employing stem cell-derived islets for disease modeling.Frontiers in bioengineering and biotechnology · 2024Article
- Global proteomics reveals insulin abundance as a marker of human islet homeostasis alterations.Acta physiologica (Oxford, England) · 2023Article
- Generation of induced pluripotent stem cell-derived beta-cells in blood amino acids-like medium.Biology open · 2023Article
- The type 1 diabetes gene TYK2 regulates β-cell development and its responses to interferon-α.Nature communications · 2022Article
- Transcription and splicing regulation by NLRC5 shape the interferon response in human pancreatic β cells.Science advances · 2022Article
- Functional, metabolic and transcriptional maturation of human pancreatic islets derived from stem cells.Nature biotechnology · 2022Article
- In depth functional characterization of human induced pluripotent stem cell-derived beta cellsFrontiers in cell and developmental biology · 2022Article
- Genome Editing and Human Pluripotent Stem Cell Technologies for in vitro Monogenic Diabetes Modeling.Diabetes, metabolic syndrome and obesity : targets and therapy · 2022Review
- Preclinical Models to Evaluate the Human Response to Autoantigen and Antigen-Specific Immunotherapy in Human Type 1 Diabetes.Frontiers in endocrinology · 2022Review
- The Human Islet: Mini-Organ With Mega-Impact.Endocrine reviews · 2021Review
- Synthetic human livers for modeling metabolic diseases.Current opinion in gastroenterology · 2021Review
- Chronically Elevated Exogenous Glucose Elicits Antipodal Effects on the Proteome Signature of Differentiating Human iPSC-Derived Pancreatic Progenitors.International journal of molecular sciences · 2021Article
- Bioengineering Clinically Relevant Cardiomyocytes and Cardiac Tissues from Pluripotent Stem Cells.International journal of molecular sciences · 2021Review
- Modeling Maturity Onset Diabetes of the Young in Pluripotent Stem Cells: Challenges and Achievements.Frontiers in endocrinology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic β-cells are the only source of insulin. Disturbances in β-cell development or function may thus result in insulin deficiency or excess, presenting as hyper- or hypoglycemia. It is increasingly evident that common forms of diabetes (types 1 and 2) are pathogenically heterogeneous. Development of efficient therapies is dependent on reliable disease models. Although animal models are remarkably useful research tools, they present limitations because of species differences. As an alternative, human pluripotent stem cell technologies offer multiple possibilities for the study of human diseases in vitro. In the last decade, advances in the derivation of induced pluripotent stem cells from diabetic patients, combined with β-cell differentiation protocols, have resulted in the generation of useful disease models for diabetes. First disease models have been focusing on monogenic diabetes. The development of genome editing technologies, more advanced differentiation protocols and humanized mouse models based on transplanted cells have opened new horizons for the modeling of more complex forms of β-cell dysfunction. We present here the incremental progress made in the modeling of diabetes using pluripotent stem cells. We discuss the current challenges and opportunities of these approaches to dissect β-cell pathology and devise new pharmacological and cell replacement therapies. Stem Cells 2019;37:33-41.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.